Once-a-Day Administration of Everolimus Is Safe in De Novo Renal Transplant Recipients: 1-Year Results of a Pilot Study

This publication has 10 references indexed in Scilit:

• Risk Factors for Cardiovascular Events After Successful Renal Transplantation
  Transplantation, 2008
• A Retrospective Analysis of Immunosuppression Compliance, Dose Reduction and Discontinuation in Kidney Transplant Recipients
  American Journal of Transplantation, 2007
• 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients
  Transplant International, 2006
• Three‐Year Efficacy and Safety Results from a Study of Everolimus Versus Mycophenolate Mofetil in de novo Renal Transplant Patients
  American Journal of Transplantation, 2005
• Everolimus and Reduced-Exposure Cyclosporine in de novo Renal-Transplant Recipients: A Three-Year Phase II, Randomized, Multicenter, Open-Label Study
  Transplantation, 2004
• Everolimus with Optimized Cyclosporine Dosing in Renal Transplant Recipients: 6-Month Safety and Efficacy Results of Two Randomized Studies
  American Journal of Transplantation, 2004
• RAPAMYCIN: CLINICAL RESULTS AND FUTURE OPPORTUNITIES1
  Transplantation, 2001
• Entry‐into‐human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients
  British Journal of Clinical Pharmacology, 1999
• A PHASE I STUDY OF A 4-WEEK COURSE OF SDZ-RAD (RAD) IN QUIESCENT CYCLOSPORINE-PREDNISONE-TREATED RENAL TRANSPLANT RECIPIENTS1,2
  Transplantation, 1999
• SDZ RAD, A NEW RAPAMYCIN DERIVATIVE
  Transplantation, 1997